4 / 4
Page 12
November 04-05, 2019 | Tokyo, Japan
6
th
INTERNATIONAL CONFERENCE ON GLOBAL HEALTHCARE
WORLD CONGRESS ON CARDIAC NURSING AND CARDIOLOGY
&
Cardiac Nursing & Global Healthcare 2019
November 04-05, 2019
The new blood thinners in atrial fibrillation, did they keep their promise a decade
later? And what about my risky older patient?
T
he emergence of new or novel therapeutic oral anticoagulants NOAC or direct as DOAC in the last decade is considered
a major contribution especially in management of the vast population suffering from atrial fibrillation AF. This is a
revolutionary step in order to improve stroke prevention measures in a large proportion of AF patients at high risk which were
not or were undertreated in VKA era in the last 50 years. AF prevalence around 1-2% of population is steadily increasing over
time and the percentage goes higher as age over 65 increases. Increased age is more prone to disabling strokes in AF and also
to increased bleeding risk following anticoagulation treatment. I' l try in my talk to review mechanism of these drugs and WHY
NOAC = DOAC = TSOAC as - target specific OA are potentially a better choice than classic VKA, What is the OAC general
importance in S\SE stroke syst emboli prevention, What the randomized multicenter clinical studies RCT's promised us, and
how to decide WHICH DOAC FOR WHOM: according to age, renal function, bleeding risk, If the studies in THE REAL
WORLD kept the promise of the RCT's, To discuss BLEEDINGS and REDUCE PARADOX concerning inadequate dosage,
Discuss importance of Antidots, and SPECIAL CONDITIONS as interruption due to invasive procedures, therapy in patients
after stenting coronaries or MI wAF and other items.
Biography
As a cardiologist head of a Coronary Care unit in my hospital and course co director in a nursing school, participating in a lot of international
randomized clinical studies, taking part as faculty in meetings until retiring, I continue nowadays to teach medical students, still treating
outpatients and a lot of patients also suffering from AF. I also am a co-editor of our national Israeli Heart Society website reviewing for our
members the published studies in the international cardiology field. In my long career I had a few older patients with AF, treated by VKA as
primary prevention only, and which passed away because of intracranial bleeds. Therefore, DOAC became a fascinating subject for me.
e
:
jackdr.goldstein@gmail.comJacob Goldstein
Lady Davis Carmel Medical Center, Israel
Current Research: Cardiology
Volume 06
Curr Res Cardiol, Volume 06